REG - GSK PLC - GSK 5-in-1 meningitis vaccine approved by US FDA

GSKAnnouncement

17/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250217:nRSQ2597Xa&default-theme=true

RNS Number : 2597X  GSK PLC  17 February 2025

 

 

Issued: 15 February 2025, London UK

 

Penmenvy, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help
protect against MenABCWY

 

·      Vaccine helps protect against five common disease-causing
serogroups of Neisseria meningitidis (A, B, C, W and Y)

·      Broad serogroup coverage in one vaccine reduces injections to
help improve vaccination rates and help protect more US adolescents and young
adults

 

 

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug
Administration (FDA) has approved Penmenvy (Meningococcal Groups A, B, C, W,
and Y Vaccine) for use in individuals aged 10 through 25 years. The vaccine
targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y)
which commonly cause invasive meningococcal disease (IMD).(1,2)

 

The vaccine combines the antigenic components of GSK's two well-established
meningococcal vaccines, Bexsero (Meningococcal Group B Vaccine) and Menveo
(Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM(197)
Conjugate Vaccine). The regulatory application
(https://www.gsk.com/en-gb/media/press-releases/gsk-s-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda/)
was supported by positive results from two phase III trials [NCT04502693
(https://clinicaltrials.gov/study/NCT04502693) ; NCT04707391
(https://www.clinicaltrials.gov/study/NCT04707391) ], which evaluated the
vaccine's safety, tolerability, and immune response in over 4,800 participants
aged 10-25 years. The safety data demonstrated that the vaccine has a safety
profile consistent with GSK's licensed meningococcal vaccines.(3-5)

 

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the
opportunities ahead to help improve meningococcal vaccination coverage in the
United States, especially for IMD caused by serogroup B. Building on our
global leadership in meningococcal vaccination and our longstanding commitment
to address unmet need in disease prevention, we aim to help protect more teens
and young adults at a life stage when they are at an increased risk."

 

Integrating GSK's MenABCWY vaccine into healthcare provider practices could
simplify meningococcal vaccination delivery and help protect more US
adolescents against these five common disease-causing serogroups - A, B, C, W,
and Y - for which the US Centers for Disease Control and Prevention (CDC) have
issued recommendations.(6) Although MenB is the leading cause of IMD among
this population, less than 13% receive the recommended two-dose vaccination
series; around 32% receive at least one dose.(7,8) Three of every four MenB
doses currently administered in the US are manufactured by GSK,(9) positioning
the company well to lead in the US market as MenB-containing vaccinations must
be completed with the same manufacturer's MenB vaccine.

 

Judy Klein, President and Founder of Unity Consortium, a non-profit
organization focused on adolescent health and immunization in the US, said:
"The consequences of IMD can be devastating for those who contract it, for
their families and friends. We welcome new tools to help protect more
adolescents from meningococcal disease. Pentavalent MenABCWY vaccines could
help address the disease by providing protection against the five
vaccine-preventable serogroups in one vaccine and making it easier for
adolescents to get the coverage they need."

 

At its meeting on February 26, 2025, the CDC's Advisory Committee on
Immunization Practices (ACIP) is expected to vote on recommendations for the
appropriate use of GSK's MenABCWY vaccine in adolescents and young adults.

 

About IMD

IMD is an uncommon but serious illness that can lead to death for up to one in
six of those who contract it in as little as 24 hours from onset, despite
treatment.(10,11) IMD is easily misdiagnosed, with early symptoms often
mistaken for the flu.(11,12) Approximately one in five survivors may
experience long-term consequences such as brain damage, amputations, hearing
loss, and nervous system problems.(10,12) Although anyone can get IMD,
adolescents and young adults between the ages of 16 and 23 years are one of
the groups at highest risk due to common behaviours that help transmit the
bacteria that cause IMD such as living in close quarters like college
dormitories, kissing and sharing drinks, utensils, or smoking devices.(13,14)

 

About Penmenvy

GSK's MenABCWY vaccine is an injectable suspension for intramuscular use. The
vaccine is supplied as one vial of lyophilized MenACWY Component (powder)
which is reconstituted at the time of use with the accompanying prefilled
syringe of MenB Component (liquid). It is indicated in the US for active
immunization to prevent invasive disease caused by Neisseria meningitidis
serogroups A, B, C, W, and Y. It is approved in the US for use in individuals
aged 10 through 25 years. The US Prescribing Information is available here
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Penmenvy/pdf/PENMENVY.PDF)
.(15)

 

About Bexsero

GSK's MenB vaccine has received regulatory approval in over 55 countries,
including the US, and is used in 18 national immunisation programmes worldwide
for the prevention of IMD caused by Neisseria meningitidis serogroup B. More
than 110 million doses have been distributed worldwide since 2015.(16) It is
supported by clinical data supporting its effectiveness in helping to protect
adolescents and young adults against diverse disease-causing strains of MenB,
with a well-characterised safety profile. In the US, this vaccine has received
regulatory approval for active immunisation to prevent invasive disease caused
by Neisseria meningitidis serogroup B and is approved for use in individuals
aged 10 through 25 years. The US Prescribing Information is available here
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF)
.
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF)
(17)

 

About Menveo

GSK's MenACWY vaccine has received regulatory approval in over 60 countries,
including the US, with more than 80 million doses distributed worldwide since
2010.(18) It offers evidence of immunogenicity with a well-characterised
safety profile. In the US, this vaccine has received regulatory approval for
active immunisation to prevent IMD caused by Neisseria meningitidis serogroups
A, C, Y, and W in individuals from 2 months through 55 years of age. The US
Prescribing Information is available here
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF)
.
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF)
(19)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Simon Moore / Dan Smith / Sarah Clements  +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn                            +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer                             +1 202 302 4595       (Washington DC)
                      Alison Hunt                               +1 540 742 3391       (Washington DC)

 Investor Relations:  Annabel Brownrigg-Gleeson                 +44 (0) 7901 101944   (London)
                      James Dodwell                             +44 (0) 20 8047 2406  (London)
                      Mick Readey                               +44 (0) 7990 339653   (London)
                      Camilla Campbell                          +44 (0) 7803 050238   (London)
                      Steph Mountifield                         +44 (0) 7796 707505   (London)
                      Jeff McLaughlin                           +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco                          +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q4 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

References:

1.     Centers for Disease Control and Prevention. About Meningococcal
Disease. Available at:
(https://www.cdc.gov/meningococcal/about/causes-transmission.html)
https://www.cdc.gov/meningococcal/about/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmeningococcal%2Fabout%2Fcauses-transmission.html.
(https://www.cdc.gov/meningococcal/about/causes-transmission.html)
(https://www.cdc.gov/meningococcal/about/causes-transmission.html) Accessed
February 2025.

2.     European Centers for Disease Control and Prevention. Factsheet
about meningococcal disease. Available at:
https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet
(https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet) . Accessed
February 2025.

3.     GSK. GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted
for regulatory review by US FDA. Available at:
https://www.gsk.com/en-gb/media/press-releases/gsk-s-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda/
(https://www.gsk.com/en-gb/media/press-releases/gsk-s-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda/)
. Accessed February 2025.

4.     NIH. Effectiveness of GlaxoSmithKline Biologicals S.A.'s
Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and
Young Adults, ClinicalTrials.gov. Available at:
https://clinicaltrials.gov/study/NCT04502693
(https://clinicaltrials.gov/study/NCT04502693) . Accessed February 2025.

5.     NIH. Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in
Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine,
ClinicalTrials.gov. Available at:
https://www.clinicaltrials.gov/study/NCT04707391
(https://www.clinicaltrials.gov/study/NCT04707391) . Accessed February 2025.

6.     Centers for Disease Control and Prevention. Meningococcal Vaccine
Recommendations. Available at:
https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html
(https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html)
. Accessed February 2025.

7.     Cheng WY, et al. Determinants of Meningococcal ACWY vaccination in
adolescents in the US: completion and compliance with the CDC recommendations.
Hum Vaccin Immunother. 2020;16(1):176-188.

8.     Centers for Disease Control and Prevention. National Vaccination
Coverage Among Adolescents Aged 13-17 Years - National Immunization
Survey-Teen, United States, 2023. Available at:
https://www.cdc.gov/mmwr/volumes/73/wr/mm7333a1.htm#:~:text=Among%20adolescents%20aged%2013%E2%80%9317%20years%20included%20in%20the%202023,view%2Fcdc%2F159388).
Accessed February 2025.

9.     Based on information licensed from IQVIA: IQVIA, DDD, Meningococcal
B market all channels, period January - December 2024, reflecting estimates of
real-world activity. All rights reserved.

10.    World Health Organisation. Meningitis fact sheet. Available at:
https://www.who.int/news-room/fact-sheets/detail/meningitis.
(https://www.who.int/news-room/fact-sheets/detail/meningitis.) Accessed April
2024.

11.    Thompson MJ, et al. Clinical recognition of meningococcal disease in
children and adolescents. Lancet. 2006;367(9508):397-403.

12.    Marshall GS, et al. Understanding the Sequelae of Invasive
Meningococcal Disease in the United States. Infect Dis Ther.
2024;13(11):2213-2220.

13.    European Centers for Disease Control and Prevention. Outbreak of
invasive meningococcal disease in the EU associated with a mass gathering
event, the 23rd World Scout Jamboree, in Japan. 21 August 2015. Available at:
https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Meningococcal-disease-scouts-EU-August-2015.pdf
(https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Meningococcal-disease-scouts-EU-August-2015.pdf)
. Accessed February 2025.

14.    Centers for Disease Control and Prevention. Risk Factors for
Meningococcal Disease. Available at:
https://www.cdc.gov/meningococcal/risk-factors/index.html
(https://www.cdc.gov/meningococcal/risk-factors/index.html) . Accessed
February 2025.

15.    GSK. US Prescribing Information for Penmenvy. Available at:
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Penmenvy/pdf/PENMENVY.PDF
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Penmenvy/pdf/PENMENVY.PDF)
. Accessed February 2025.

16.    GSK Data on File. Number of Bexsero doses shipped from 2015 to
November 2023 REF-219766

17.    GSK. US Prescribing Information for Bexsero. Available at:
gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF)
.
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF)
Accessed February 2025.

18.    GSK Data on File. Menveo Doses Shipped from 2010 to end of 2022
REF-195452

19.    GSK. Prescribing Information for Menveo. Available at:
gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF)
.
(https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF)
Accessed February 2025.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REALELBFELLXBBV